This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Drug induced hyperprolactinaemia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The main drugs which induce hyperprolactinaemia are:

  • major tranquilisers - block dopamine binding sites
  • metoclopramide - block dopamine binding sites
  • tricyclic antidepressants - block catecholamine re-uptake
  • reserpine - depletes catecholamines
  • methyl-dopa - blocks conversion of tyrosine to dihydroxyphenylalanine and dopamine
  • oral contraceptives - promote the synthesis and storage of prolactin
  • bendrofluazide, omeprazole, ranitidine, cimetidine and famotidine have occasionally been reported to cause hyperprolactinaemia

Drug-induced increases in serum prolactin do not generally lead to levels above 2500 mU/L; however occasionally levels up to 6000 mU/L have been observed (1).

In cases of suspected drug-induced hyperoprolactinaemia where very high levels of prolactin are seen (over 2500 mU/L) then detailed physical examination (including visual fields), pituitary imaging and measurement of pituitary hormone levels are indicated.

Reference:

  • (1) Prescribers' Journal (2000), 40 (2), 157-168.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.